Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corporation reports developments as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. Company updates center on its RAP Platform, regRNA mapping, antisense oligonucleotide candidates and CMP-002 for SYNGAP1-related disorder, along with regulatory submissions, orphan-drug designation and natural-history research collaborations.
Recurring news also includes financial results, research and development spending, financing activity, business-development agreements such as the GSK collaboration, board and governance changes, inducement equity grants under Nasdaq rules and investor conference participation.
CAMP4 Therapeutics (Nasdaq: CAMP) closed the second tranche of its previously announced $100 million private placement, raising approximately $50.1 million in gross proceeds. The financing comprised 10,756,498 common shares at $1.53, 39,306 common shares to insiders at $1.65, and 21,925,368 pre-funded warrants at $1.5299 each.
According to CAMP4 Therapeutics, net proceeds will support advancement of CMP-002, including a planned Phase 1/2 trial in SYNGAP1-related disorder in Australia, and ongoing development of its early-stage pipeline. The round included several institutional investors and was led by Leerink Partners as placement agent.
CAMP4 Therapeutics (Nasdaq: CAMP) received clearance from Australia’s Therapeutic Goods Administration and a local Human Research Ethics Committee to initiate a Phase 1/2 first-in-human clinical trial of CMP-002, a potential first-in-class disease-modifying therapeutic for SYNGAP1-related disorder, which currently has no approved treatments.
The TGA clearance also triggers a regulatory milestone under CAMP4’s September 9, 2025 Securities Purchase Agreement. According to the company, CAMP4 previously received approximately $50 million in gross proceeds and is now eligible to raise up to an additional $50 million in gross proceeds through a second closing, issuing up to 32,721,172 shares of common stock or pre-funded warrants. The second closing is expected within five business days, subject to customary conditions, with participation from investors including Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management, Trails Edge Capital Partners, and CURE SYNGAP1.
CAMP4 Therapeutics (Nasdaq: CAMP) reported that on July 15, 2026, its Board Compensation Committee granted a non-qualified stock option to purchase 8,000 shares of common stock to a new employee as an inducement grant under Nasdaq Listing Rule 5635(c)(4).
The option has a 10-year term and an exercise price of $4.21 per share, equal to the closing price on the grant date. Vesting occurs over four years: 25% after one year of employment, then the remaining shares vest in 36 equal monthly installments, subject to continued service. The grant is made under the company’s 2026 Inducement Plan and related stock option agreement.
CAMP4 Therapeutics (Nasdaq:CAMP) granted non-qualified stock options to three new employees under Nasdaq Listing Rule 5635(c)(4). The inducement awards cover an aggregate 39,000 shares at an exercise price of $3.96 per share, equal to the June 15, 2026 closing price.
The options have a 10-year term and vest over four years: 25% after one year of employment, then the remainder in 36 equal monthly installments, subject to continued service. The grants are issued under CAMP4’s 2026 Inducement Plan and related stock option agreements.
CAMP4 Therapeutics (Nasdaq:CAMP) granted a non-qualified stock option to purchase 5,000 shares of common stock to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).
The option has a 10-year term, an exercise price of $4.31, and vests over four years.
CAMP4 Therapeutics (Nasdaq:CAMP) reported new preclinical data for CMP-002, its lead antisense oligonucleotide for SYNGAP1-related disorder (SRD). In a SYNGAP1 haploinsufficient mouse model using pentylenetetrazol-induced seizures, CMP-002 administration produced statistically significant improvements in seizure threshold and tonic-clonic seizure severity. CAMP4 plans to advance CMP-002 into a Phase 1/2 trial in SRD in the second half of 2026.
CAMP4 (Nasdaq: CAMP) reported Q1 2026 results and corporate highlights on May 7, 2026. Key updates: submitted first regulatory filing for CMP-002 in Australia to enable a global Phase 1/2 SYNGAP1 trial in 2H 2026; EMA granted Orphan Designation for CMP-002; collaboration established with CURE SYNGAP1 for the ProMMiS natural history study. As of March 31, 2026, cash and cash equivalents were $99.2M, with the company estimating runway into 2028. Q1 operating highlights include R&D $10.2M, G&A $4.2M, and net loss $18.3M, which included a $6.2M non-cash derivative loss.
CAMP4 Therapeutics (Nasdaq: CAMP) submitted a preprint (April 28, 2026) describing regRNA Capture-seq and epigenomic mapping that assembled what the company believes is the largest catalog of regulatory RNAs in human liver cells and enabled discovery of antisense oligonucleotides (ASOs) that increased OTC expression in human hepatocytes.
The preprint outlines mechanistic studies of ASOs reshaping regRNA, displacing repressors at an enhancer, and identifies lead candidate CMP-002 for SYNGAP1, expected to enter Phase 1/2 in H2 2026.
CAMP4 (Nasdaq: CAMP) granted non-qualified stock options totaling 43,000 shares on April 15, 2026 as inducement awards to three newly hired employees under Nasdaq Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $4.59 per share (closing price on the grant date) and vest over four years (25% at one year, then monthly over 36 months).
CAMP4 (Nasdaq: CAMP) appointed Michael MacLean to its Board of Directors on March 24, 2026.
Mr. MacLean brings 35+ years of financial leadership in biotech, including service as CFO at Avidity Biosciences through its 2020 IPO and its acquisition by Novartis in 2026, and senior finance roles at Akcea, PureTech, and Biogen. The appointment coincides with CAMP4 advancing CMP-002 toward a planned first-in-human Phase 1/2 trial for SYNGAP1-related disorder.